| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 31, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2024 | $4.50 | Overweight | Piper Sandler |
| 2/2/2022 | $6.00 | Buy | HC Wainwright & Co. |
| 1/24/2022 | $10.00 | Buy | ThinkEquity |
Piper Sandler initiated coverage of Centrexion Therapeutics with a rating of Overweight and set a new price target of $4.50
HC Wainwright & Co. initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $6.00
ThinkEquity initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $10.00
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr. Karen Smith and Dr. Luke Walker Cash and cash equivalents of $84.8 million as of September 30, 2024 PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced its financial results for the third quarter ended September 30, 2024, and reported on recent and upcoming business highlights. "Context executed on its strategy to bui
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November: Guggenheim Global Healthcare Conference: Fireside chat on Monday, November 11, 2024, at 3:00 p.m. ET in Boston, MA. UBS Global Healthcare Conference: Fireside chat on Wednesday, November 13, 2024, at 11:45 a.m. PT in Rancho Palos Verdes, CA. Stifel 2024 Healthcare Conference: Presentation on Tuesday, November 19, 2024 at 1:50 p.m. ET in New York, NY. Context will also participate in one-on-one meetings a
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title:Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6Authors:Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, Eric ButzAbstract Number:
S-3 - Context Therapeutics Inc. (0001842952) (Filer)
10-Q - Context Therapeutics Inc. (0001842952) (Filer)
8-K - Context Therapeutics Inc. (0001842952) (Filer)
PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. "Karen and Luke's vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth," said Martin Lehr, CEO of Context Therapeutics. "Karen's extensive oncology drug development, regulatory, and strategy experience will be invaluable as Context continues to advance its pipeline. Luke brings an extensive track record in
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company's two clinical-stage T cell engaging assets to treat solid tumors PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer ("CMO") and Karen Andreas, M.S. as Vice President, Clinical Operations. "We are thrilled to welcome Dr. Dansky Ullmann and Ms. Andreas to our team at this exciting time as the Company adv
PHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (NASDAQ:CNTX), a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announced the appointment of Jennifer Minai-Azary as Chief Financial Officer and the prior appointment, in April 2021, of Alex Levit as Chief Legal Officer. "It is an exciting time for the company following our recent debut on Nasdaq and I'd like to thank Alex for all of his contributions to help make this happen. I'm also pleased to welcome Jennifer Minai-Azary to Context's leadership team," said Martin Lehr, Chief Executive Officer of
4 - Context Therapeutics Inc. (0001842952) (Issuer)
3 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
SC 13G - Context Therapeutics Inc. (0001842952) (Subject)
SC 13G - Context Therapeutics Inc. (0001842952) (Subject)
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr. Karen Smith and Dr. Luke Walker Cash and cash equivalents of $84.8 million as of September 30, 2024 PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced its financial results for the third quarter ended September 30, 2024, and reported on recent and upcoming business highlights. "Context executed on its strategy to bui
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and reported on recent business highlights. "Context continues to build momentum, and we believe the Company is well positioned to have a successful year," said Martin Lehr, CEO of Context. "Our team recently initiated our Phase 1 trial
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, Inc. ("Link"), a mesothelin ("MSLN") x CD3 T cell engaging ("TCE") bispecific antibody with first-in-class potential that has received Investigational New Drug ("IND") clearance from th
HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price target.
CT-95, formerly owned by Link Immunotherapeutics, a mesothelin x CD3 T cell engaging bispecific antibody with first-in-class potential that has received Investigational New Drug clearance from the U.S. Food and Drug Administration. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. CT-95 is an IND-cleared asset that it plans to rapidly progress into clinical trials. It intends to fund the acquisition of CT-95 and its advancement through the dose escalation portion of a Phase 1 clinical trial with existing cash.
- SEC Filing